Novartis AG has won U.S. Food and Drug Administration approval for multiple scle...
ZURICH - Novartis AG has won U.S. Food and Drug Administration approval for multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition.
Mayzent was approved for adults with relapsing forms of the disease, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease , the FDA said. It said the drug’s benefits were not statistically significant in patients with non-active MS. So far, however, ICER has concluded Novartis would have to price Mayzent between $680 and $1,000 per month for it be considered cost-effective.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Novartis new MS drug Mayzent to be priced at $88,000 per yearNovartis will price its new Mayzent multiple sclerosis drug at $88,000 dollars p...
Baca lebih lajut »
A young liberal is poised to win Slovakia’s presidencyMs Caputova took 41% of the vote in the first round of Slovakia's presidential election. She looks set to win the run-off
Baca lebih lajut »
Novartis new MS drug Mayzent to be priced at $88,000 per yearNovartis will price its new Mayzent multiple sclerosis drug at $88,000 dollars p...
Baca lebih lajut »
Novartis gets U.S. approval for new drug to treat multiple sclerosisNovartis AG won U.S. Food and Drug Administration approval on Tuesday for its ne...
Baca lebih lajut »